Complex ADC Process Development: What to Look for in a CDMO Partner

The emergence of bispecific ADCs, dual-payload ADCs, and site-specific conjugation technologies is reshaping ADC process development. Compared with conventional ADCs, these increasingly sophisticated molecules require tighter control over conjugation chemistry, analytical characterization, formulation, and manufacturing scalability.

As next-generation ADC modalities continue to advance into clinical development, process complexity is becoming a key determinant of CMC success. For many programs, the primary challenge is no longer whether a molecule can be synthesized, but whether it can be consistently manufactured, comprehensively characterized, and reliably scaled up for clinical and commercial production.

This article explains the major process development challenges associated with complex ADCs, the technical capabilities a CDMO should provide, and why early CMC integration matters when moving these programs toward GMP manufacturing.

Complex ADCs Require Tighter Process and Quality Control

As ADC technologies continue to evolve, bispecific ADCs, dual-payload ADCs, and site-specific conjugation technologies are introducing new challenges for process development. Compared with conventional ADCs, these increasingly complex designs demand tighter control over conjugation chemistry, product heterogeneity, and manufacturing consistency.

Small process variations can affect critical quality attributes (CQAs), including:

As a result, process development must focus not only on manufacturing feasibility, but also on analytical characterization, process robustness, and scalability to support downstream CMC development and regulatory expectations.

Four Technical Capabilities Should Are Central to Complex ADX Development

Selecting a CDMO for complex ADC development requires evaluating technical expertise across the entire CMC workflow rather than focusing only on manufacturing capacity.

More sophisticated molecular designs often require tighter control of conjugation reactions to achieve consistent DAR, payload distribution, and product homogeneity. Process parameters that are acceptable for conventional ADCs may have a greater impact on product quality in more complex formats.

As molecular complexity increases, analytical requirements also expand.

Beyond routine DAR determination, developers often need orthogonal analytical methods to characterize:

These methods provide a comprehensive understanding of product quality throughout development.

Complex ADCs may exhibit greater sensitivity to formulation conditions during manufacturing and storage.

Early formulation screening can include:

These activities help reduce downstream development risk and supports product consistency.

Laboratory-scale success does not guarantee manufacturing success. Understanding how critical process parameters influence CQAs is essential for establishing a scalable process that can support technology transfer, process validation, and GMP production.

Early CMC Integration Reduces Redevelopment Risk

For complex ADCs, process development should not be viewed as an isolated activity. Decisions made during conjugation development can directly affect analytical strategies, formulation performance, process validation, and manufacturing consistency.

Integrating process development with analytical development, formulation, and CMC activities allows technical risks to be identified earlier and reduces the need for redevelopment during later stages. This approach also improves process knowledge, strengthens regulatory readiness, and facilitates a smoother transition from development to GMP manufacturing.

CDMO Selection Should Focus on Integrated Development Capability

As complex ADCs progress toward clinical development, development capability becomes as important as manufacturing capacity.

For complex ADC programs, an ideal CDMO should provide integrated expertise across:

Experience with bispecific antibodies and dual-payload ADCs is equally important, as these increasingly sophisticated formats introduce additional challenges during process optimization, scale-up, and CMC development.

Rather than evaluating individual capabilities in isolation, biopharma companies should look for a partner that can support the entire process development workflow under a coordinated CMC strategy.

How ChemExpress Supports Complex ADC Process Development

ChemExpress supports this integrated approach through capabilities spanning process development, analytical development, formulation, CMC, and GMP manufacturing.

The company has supported multiple bispecific ADC programs and completed early-stage process verification for dual-payload ADCs, helping bridge emerging ADC modalities with scalable process development.

FAQ

Q1: Why is process development more challenging for complex ADCs than conventional ADCs?

A: Complex ADCs often exhibit greater molecular heterogeneity and require tighter control over conjugation chemistry, analytical characterization, and process consistency throughout development.

Q2: What analytical capabilities are essential for complex ADC process development?

A: Comprehensive characterization typically includes DAR analysis, payload distribution, free payload determination, aggregation assessment, charge variant analysis, and structural characterization using complementary analytical techniques.

Q3: Why are scale-up and technology transfer more challenging for bispecific and site-specific ADCs?

A: Bispecific antibodies are often sensitive to shear stress and organic solvent exposure during conjugation. Small shifts in vessel geometry, impeller tip speed, or local mixing rates during scale-up can cause localized over-conjugation or protein aggregation, altering the drug-antibody ratio (DAR).

Q4: Why is early CMC integration important for complex ADCs?

A: Early integration connects process development with analytical development, formulation, scale-up, and manufacturing, reducing technical risk and minimizing redevelopment during later development stages.

Q5: Does experience with bispecific or dual-payload ADCs matter when selecting a CDMO?

A: Yes. Emerging ADC modalities often require more sophisticated process development than conventional ADCs because they involve greater molecular complexity and tighter control over conjugation, analytical characterization, and manufacturability. A CDMO with hands-on experience in bispecific antibodies or dual-payload ADC development is generally better positioned to anticipate technical challenges and support efficient CMC progression. ChemExpress has supported multiple bispecific ADC programs, completed early-stage process verification for dual-payload ADCs, and provides integrated development capabilities from process development through GMP manufacturing.